StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Investment analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Down 7.9 %

CHEK opened at $0.70 on Wednesday. Check-Cap has a 1-year low of $0.68 and a 1-year high of $3.45. The company has a market cap of $4.12 million, a price-to-earnings ratio of -0.23 and a beta of 0.25. The company’s fifty day moving average price is $1.09 and its two-hundred day moving average price is $1.65.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.